The proteasome inhibitor bortezomib is able to block the degradation of the classical IκB proteins and has been approved for multiple myeloma therapy, although it remains unclear if the beneficial effect of bortezomib can be attributed solely to NF-κB inhibition [212,213,214]. The gene discussed is NFKB1; the disease is AL amyloidosis.